SGLT-2 Therapy Center

New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of empagliflozin in patients with type 2 and cardiovascular disease.

Dr. George Bakris talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about the possible kidney benefits for those using SGLT-2s.

Dr. Davidson discusses new diabetes drugs and their impact on patient health, including DKA; new combination drugs; and the expensive side effects of sulfonylureas.

In this Exclusive Interview, Dr. Davidson discusses his thoughts on new drugs and their impact on patient health, such as DKA.

Apart from Sotagliflozin’s use in the treatment of people with type 2, SGLT-1 and SGLT-2 inhibitors effects on type 1 currently being explored.

CANVAS Program results confirm cardiovascular benefits are SGLT-2 Inhibitor Class effect.

Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research. This week, we have an exclusive interview from ADA 2017. The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Dr. Bruce Neal.

Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 1 of this ...

Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 2 of this exclusive ...

Diabetes In Control Publisher Steve Freed speaks with CANVAS study lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California. In Part 3 of this exclusive ...